BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

...EMA for the therapy by year-end. June PDUFA date for Vericel, MediWound burn therapyVericel Corp. (NASDAQ:VCEL) and MediWound Ltd....
...is June 29, 2021.TARGETSHsp70 – heat shock protein 70 BC Staff NexoBrid (debrase gel dressing) arimoclomol (BRX-345, OR-01) ARO-AAT Vericel Corp. MediWound Ltd. Orphazyme...
BioCentury | Jun 11, 2019
Company News

Management Tracks: Agios’ Biller to retire as CSO; plus Vectura, Molecular Partners, F-star and more

...Notal Vision Inc. (Manassas, Va.); Saim was VP, pharmaceutical development at Collegium Pharmaceutical Inc. (NASDAQ:COLL). MediWound Ltd....
...Israel), both of which he co-founded. BioCentury Staff Agios Pharmaceuticals Inc. Biophytis S.A. Celsius Therapeutics Inc. eGenesis Inc. EyePoint Pharmaceuticals Inc. Medicure Inc. MediWound Ltd. Molecular...
BioCentury | Jan 25, 2019
Clinical News

MediWound planning BLA for thermal burn agent

...thermal burns. The company plans to submit a BLA to FDA next half for NexoBrid. MediWound...
...and Russia to remove eschar in adults with deep partial and full thickness thermal burns. MediWound Ltd....
...of complete eschar removal Status: Phase III data Milestone: Submit BLA (2H19) Sandi Wong NexoBrid (debrase gel dressing) MediWound Ltd. Burns eschar...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...HedgePath Pharmaceuticals Inc. (OTCQX:HPPI) SUBA-Itraconazole Basal cell carcinoma nevus syndrome (Gorlin syndrome) Submit NDA 4Q18 MediWound Ltd....
BioCentury | Oct 6, 2017
Finance

High as a Kite

...NASDAQ:IOVA) 9/20/17 $57.5 $465.0 $554.4 19% Aldeyra Therapeutics Inc. (NASDAQ:ALDX) 9/19/17 $28.8 $138.6 $137.6 -1% MediWound Ltd....
BioCentury | Sep 22, 2017
Financial News

MediWound prices $22M follow-on

...On Sept. 19, dermatology company MediWound Ltd. (NASDAQ:MDWD) raised $22 million through the sale of 4.4 million...
...by Cowen, Wells Fargo, Oppenheimer, SunTrust Robinson Humphrey and Aegis Capital. MediWound Ltd. (NASDAQ:MDWD), Yavne, Israel Jennie Walters MediWound Ltd....
BioCentury | Feb 8, 2016
Clinical News

EscharEx: Phase II data

...enrolled patients with diabetic foot ulcers, venous leg ulcers and postsurgical or traumatic hard-to-heal wounds. MediWound Ltd....
BioCentury | Oct 12, 2015
Company News

MediWound, U.S. Department of Health and Human Services dermatology news

...HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded MediWound a contract worth up to $112...
...additional $22 million to expand NexoBrid’s indications, plus up to $50 million for additional procurement. MediWound...
...EU and Israel to remove eschar in adults with deep partial and full-thickness thermal burns. MediWound Ltd....
BioCentury | Sep 7, 2015
Clinical News

EscharEx: Completed Phase II enrollment

...EscharEx. The wounds include diabetic foot ulcers, venous ulcers and postsurgical or traumatic hard-to-heal wounds. MediWound Ltd....
BioCentury | Jun 2, 2014
Clinical News

EscharEx: Phase II started

...other hard-to-heal wounds, including diabetic foot ulcers, venous ulcers and post-surgical or traumatic hard-to-heal wounds. MediWound Ltd....
Items per page:
1 - 10 of 25
BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

...EMA for the therapy by year-end. June PDUFA date for Vericel, MediWound burn therapyVericel Corp. (NASDAQ:VCEL) and MediWound Ltd....
...is June 29, 2021.TARGETSHsp70 – heat shock protein 70 BC Staff NexoBrid (debrase gel dressing) arimoclomol (BRX-345, OR-01) ARO-AAT Vericel Corp. MediWound Ltd. Orphazyme...
BioCentury | Jun 11, 2019
Company News

Management Tracks: Agios’ Biller to retire as CSO; plus Vectura, Molecular Partners, F-star and more

...Notal Vision Inc. (Manassas, Va.); Saim was VP, pharmaceutical development at Collegium Pharmaceutical Inc. (NASDAQ:COLL). MediWound Ltd....
...Israel), both of which he co-founded. BioCentury Staff Agios Pharmaceuticals Inc. Biophytis S.A. Celsius Therapeutics Inc. eGenesis Inc. EyePoint Pharmaceuticals Inc. Medicure Inc. MediWound Ltd. Molecular...
BioCentury | Jan 25, 2019
Clinical News

MediWound planning BLA for thermal burn agent

...thermal burns. The company plans to submit a BLA to FDA next half for NexoBrid. MediWound...
...and Russia to remove eschar in adults with deep partial and full thickness thermal burns. MediWound Ltd....
...of complete eschar removal Status: Phase III data Milestone: Submit BLA (2H19) Sandi Wong NexoBrid (debrase gel dressing) MediWound Ltd. Burns eschar...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...HedgePath Pharmaceuticals Inc. (OTCQX:HPPI) SUBA-Itraconazole Basal cell carcinoma nevus syndrome (Gorlin syndrome) Submit NDA 4Q18 MediWound Ltd....
BioCentury | Oct 6, 2017
Finance

High as a Kite

...NASDAQ:IOVA) 9/20/17 $57.5 $465.0 $554.4 19% Aldeyra Therapeutics Inc. (NASDAQ:ALDX) 9/19/17 $28.8 $138.6 $137.6 -1% MediWound Ltd....
BioCentury | Sep 22, 2017
Financial News

MediWound prices $22M follow-on

...On Sept. 19, dermatology company MediWound Ltd. (NASDAQ:MDWD) raised $22 million through the sale of 4.4 million...
...by Cowen, Wells Fargo, Oppenheimer, SunTrust Robinson Humphrey and Aegis Capital. MediWound Ltd. (NASDAQ:MDWD), Yavne, Israel Jennie Walters MediWound Ltd....
BioCentury | Feb 8, 2016
Clinical News

EscharEx: Phase II data

...enrolled patients with diabetic foot ulcers, venous leg ulcers and postsurgical or traumatic hard-to-heal wounds. MediWound Ltd....
BioCentury | Oct 12, 2015
Company News

MediWound, U.S. Department of Health and Human Services dermatology news

...HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded MediWound a contract worth up to $112...
...additional $22 million to expand NexoBrid’s indications, plus up to $50 million for additional procurement. MediWound...
...EU and Israel to remove eschar in adults with deep partial and full-thickness thermal burns. MediWound Ltd....
BioCentury | Sep 7, 2015
Clinical News

EscharEx: Completed Phase II enrollment

...EscharEx. The wounds include diabetic foot ulcers, venous ulcers and postsurgical or traumatic hard-to-heal wounds. MediWound Ltd....
BioCentury | Jun 2, 2014
Clinical News

EscharEx: Phase II started

...other hard-to-heal wounds, including diabetic foot ulcers, venous ulcers and post-surgical or traumatic hard-to-heal wounds. MediWound Ltd....
Items per page:
1 - 10 of 25